Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of IPD.AX is 0.11 and suggests 206% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell